| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Sirtuin modulator 2 targets sirtuins, a family of NAD⁺-dependent deacetylases that play important roles in cellular regulation. The compound is a sirtuin modulator, meaning it modulates the activity of these enzymes. It has a broad range of bioactivities including inhibition of Lamin A splicing, DNA Polymerase Beta, BAZ2B, ROR gamma transcriptional activity, and firefly luciferase. These activities suggest it may have multiple mechanisms of action.
|
|---|---|
| ln Vitro |
In vitro, Sirtuin modulator 2 is a sirtuin modulator with an ED50 not exceeding 50 μM. It exhibits antidiabetic, anti-inflammatory, and antitumor activities. The compound inhibits the splicing of Lamin A, inhibits DNA Polymerase Beta, inhibits BAZ2B, inhibits ROR gamma transcriptional activity, and inhibits firefly luciferase. These diverse activities make it a useful tool for studying various biological processes.
|
| ln Vivo |
Specific in vivo data for Sirtuin modulator 2 are limited. Based on its in vitro activities, the compound has potential for studying diabetes, inflammation, and cancer. However, detailed in vivo efficacy studies in animal models have not been extensively reported. The compound is primarily used as a research tool.
|
| Enzyme Assay |
In vitro enzyme assays for Sirtuin modulator 2 measure its modulation of sirtuin activity. Sirtuins are incubated with varying concentrations of the compound, an acetylated peptide substrate, and NAD⁺. Deacetylation is measured, and the ED50 is determined from dose-response curves. Additional assays measure inhibition of Lamin A splicing, DNA Polymerase Beta, BAZ2B, ROR gamma, and luciferase.
|
| Cell Assay |
Cell-based assays for Sirtuin modulator 2 are conducted in relevant cell lines. Cells are treated with the compound, and sirtuin activity is assessed by measuring the acetylation status of sirtuin substrates. Cell viability, inflammatory markers, and other relevant endpoints are also assessed.
|
| Animal Protocol |
In vivo animal experiments with Sirtuin modulator 2 have not been extensively documented. Typical study designs would involve administration of the compound in models of diabetes, inflammation, or cancer. Dosing regimens and routes of administration would need to be optimized. The compound is for research use only.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Sirtuin modulator 2 are not extensively characterized. The compound has a molecular formula of C19H15N3O2S and a molecular weight of 349.41. Storage: long-term in a cool, dry place. Specific data on absorption, distribution, metabolism, and excretion are not available.
|
| Toxicity/Toxicokinetics |
Safety and toxicology data for Sirtuin modulator 2 are limited. The compound is for research use only and is not approved for human therapeutic use. Standard laboratory safety precautions should be followed when handling the compound. No specific toxicity data are available.
|
| References | |
| Additional Infomation |
Sirtuin modulator 2 has CAS number 667910-69-2, molecular formula C19H15N3O2S, and molecular weight 349.41. Synonyms: compound 132. It is a sirtuin modulator with ED50 ≤ 50 μM. It exhibits antidiabetic, anti-inflammatory, and antitumor activities. Purity: 98%. Not for human use; for research purposes only.
|
| Molecular Formula |
C19H15N3O2S
|
|---|---|
| Molecular Weight |
349.406
|
| Exact Mass |
349.088
|
| CAS # |
667910-69-2
|
| PubChem CID |
752438
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
4.3
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
25
|
| Complexity |
478
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S1C=CN2C=C(C3C=CC=C(NC(=O)C4=CC=CC=C4OC)C=3)N=C12
|
| InChi Key |
BPCBHLCQTLAFBG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H15N3O2S/c1-24-17-8-3-2-7-15(17)18(23)20-14-6-4-5-13(11-14)16-12-22-9-10-25-19(22)21-16/h2-12H,1H3,(H,20,23)
|
| Chemical Name |
N-(3-imidazo[2,1-b][1,3]thiazol-6-ylphenyl)-2-methoxybenzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~286.20 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.15 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (7.15 mM) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8620 mL | 14.3098 mL | 28.6197 mL | |
| 5 mM | 0.5724 mL | 2.8620 mL | 5.7239 mL | |
| 10 mM | 0.2862 mL | 1.4310 mL | 2.8620 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
